Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Free Cash Flow (2016 - 2025)

Editas Medicine (EDIT) has disclosed Free Cash Flow for 11 consecutive years, with -$31.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 33.72% to -$31.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$180.1 million, a 0.43% change, with the full-year FY2024 number at -$210.3 million, down 58.13% from a year prior.
  • Free Cash Flow was -$31.4 million for Q3 2025 at Editas Medicine, up from -$50.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$19.7 million in Q4 2023 to a low of -$60.8 million in Q2 2024.
  • A 5-year average of -$43.3 million and a median of -$42.0 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 51.09% in 2023, then plummeted 157.68% in 2024.
  • Editas Medicine's Free Cash Flow stood at -$42.0 million in 2021, then grew by 4.15% to -$40.2 million in 2022, then skyrocketed by 51.09% to -$19.7 million in 2023, then plummeted by 157.68% to -$50.7 million in 2024, then skyrocketed by 38.08% to -$31.4 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Free Cash Flow are -$31.4 million (Q3 2025), -$50.2 million (Q2 2025), and -$47.8 million (Q1 2025).